Dulaglutide vs Retatrutide

Dulaglutide (brand name Trulicity) is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes and reduce cardiovascular risk. Retatrutide, still in development, is a triple-action drug that targets GIP, GLP-1, and glucagon receptors, but it has not yet received FDA approval for any use.

AI summary of the sources below.